ERBB2 and breast cancer: DESTINY-Breast 01 was a single arm, phase 2 study in which 184 patients with heavily pretreated (median number of prior lines of treatment was 6, range 2–27) HER2-positive advanced breast cancer were treated with T-DXd [33].